[
  {
    "ts": null,
    "headline": "Is Amgen Stock Outperforming the Dow?",
    "summary": "Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=b240ce9dff5ccec884c97f1d05558a56a8fcdad40ff1167a56f0d0769776bd8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772023934,
      "headline": "Is Amgen Stock Outperforming the Dow?",
      "id": 139215542,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=b240ce9dff5ccec884c97f1d05558a56a8fcdad40ff1167a56f0d0769776bd8e"
    }
  },
  {
    "ts": null,
    "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "summary": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772013790,
      "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
      "id": 139209740,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09"
    }
  },
  {
    "ts": null,
    "headline": "These 4 charts show the scale of Novo Nordisk's woes",
    "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
    "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771997562,
      "headline": "These 4 charts show the scale of Novo Nordisk's woes",
      "id": 139212445,
      "image": "https://image.cnbcfm.com/api/v1/image/108245068-1766477256303-gettyimages-2228673815-raa-novonord250809_npj4Z.jpeg?v=1768247892&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
      "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f"
    }
  }
]